Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Lowered by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. trimmed its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 19.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 63,220 shares of the biopharmaceutical company’s stock after selling 14,875 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Ultragenyx Pharmaceutical were worth $2,660,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 103.8% during the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock valued at $76,065,000 after acquiring an additional 942,529 shares during the last quarter. Alkeon Capital Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 34.3% during the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after purchasing an additional 769,884 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Ultragenyx Pharmaceutical by 123.4% in the 3rd quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock valued at $54,872,000 after purchasing an additional 545,600 shares during the period. Frazier Life Sciences Management L.P. purchased a new position in Ultragenyx Pharmaceutical in the 2nd quarter worth about $17,468,000. Finally, Ikarian Capital LLC acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth about $9,943,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the transaction, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. The trade was a 0.38 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.80% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $40.85 on Friday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $37.02 and a fifty-two week high of $60.37. The stock’s 50-day moving average is $45.30 and its two-hundred day moving average is $49.52.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same period in the previous year, the company earned ($2.23) EPS. The company’s revenue for the quarter was up 42.3% on a year-over-year basis. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on RARE. Piper Sandler raised their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday. JPMorgan Chase & Co. lowered their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Royal Bank of Canada reissued an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Canaccord Genuity Group restated a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Finally, Wedbush reiterated a “neutral” rating and issued a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $92.29.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.